Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year

SAN DIEGO, CA / ACCESS Newswire / November 20, 2025 /Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing ...

Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference

New lecanemab findings highlight the safety and potential benefits of subcutaneous administration for initiation dosing, the potential for additional long-term clinical benefits with continued ...

Nasus Pharma, Ltd.: Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed

The Phase 2 study is designed to address regulatory approval considerations by comparing bioavailability and pharmacokinetics of NS002 against EpiPen Previous clinical study demonstrated NS002 can ach ...

Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed

The Phase 2 study is designed to address regulatory approval considerations by comparing bioavailability and pharmacokinetics of NS002 against ...